-
Mashup Score: 25Events | Verve Therapeutics - 8 hour(s) ago
The Investor Relations website contains information about Verve Therapeutics’s business for stockholders, potential investors, and financial analysts.
Source: ir.vervetx.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 25Events | Verve Therapeutics - 1 day(s) ago
The Investor Relations website contains information about Verve Therapeutics’s business for stockholders, potential investors, and financial analysts.
Source: ir.vervetx.comCategories: General Medicine News, CardiologistsTweet-
Join us for our presentation today at #JPM2025 Webcast here https://t.co/AJMCISddke at 11:15 AM PT (2:15 PM ET) Deck here: https://t.co/Xp2KEvSZK3 https://t.co/x1LqNgRQ5x
-
-
Mashup Score: 15
BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced underwritten
Source: ir.vervetx.comCategories: General Medicine News, CardiologistsTweet-
Deal closed today with full exercise of green shoe Overall gross proceeds $167M, cash runway into late '26 Base offering: $125M Shoe: $18.75M Private placement to Lilly: $23M https://t.co/7MnAvDwCdT
-
-
Mashup Score: 198Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement | Verve Therapeutics - 1 year(s) ago
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of an underwritten public offering of
Source: ir.vervetx.comCategories: General Medicine News, CardiologistsTweet-
completed $148M raise ($125M offering, $23M private placement with @EliLillyandCo) post raise, 3y cash runway, now into late 2026. @VerveTx $VERV https://t.co/aNWuPYLcoV
-
-
Mashup Score: 4Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results | Verve Therapeutics - 1 year(s) ago
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Collaboration with Eli Lilly and Company (Lilly) Expands Through Lilly’s Acquisition of Product Rights to Verve’s PCSK9 and ANGPTL3
Source: ir.vervetx.comCategories: General Medicine News, Cardiology News and JournTweet-
#CVDPrevention at #AHA23 @VerveTx Sunday | 3:30 – 3:40 reporting initial safety, tolerability & pharmacodynamic data, & changes in blood PCSK9 protein & LDL-C levels, from patients across 4 single-ascending dose cohorts in VERVE-101. @drmarthagulati https://t.co/livv8oG1aG https://t.co/v8W6K2rHT3
-
-
Mashup Score: 5
BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the lifting of the clinical hold and clearance of its
Source: ir.vervetx.comCategories: General Medicine News, CardiologistsTweet-
Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in #HeFH https://t.co/mJeucuXvfM
-
Join us for our presentation today at #JPM2025 Webcast here https://t.co/AJMCISddke at 11:15 AM PT (2:15 PM ET) Deck here: https://t.co/Xp2KEvSZK3 https://t.co/x1LqNgRQ5x